A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

Rizzieri, David A ; Feldman, Eric ; Dipersio, John F ; Gabrail, Nashat ; Stock, Wendy ; Strair, Roger ; Rivera, Victor M ; Albitar, Maher ; Bedrosian, Camille L ; Giles, Francis J

Clinical cancer research, 2008-05, Vol.14 (9), p.2756-2762 [Periódico revisado por pares]

United States: American Association for Cancer Research

Texto completo disponível